News
07-11-2018, 06:43 AM
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib with T-DM1 against heavily pretreated HER2-positive breast cancer.
More... (https://www.news-medical.net/news/20180711/Clinical-trial-results-of-tucatinib-with-T-DM1-shows-promise-in-treating-HER22b-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20180711/Clinical-trial-results-of-tucatinib-with-T-DM1-shows-promise-in-treating-HER22b-breast-cancer.aspx)